Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming ...

Meanwhile, Leqselvi's launch is now delayed as Sun and rival JAK drug developer Incyte are locked in a patent fight. Fortress Biotech, which founded Checkpoint and holds a majority of Checkpoint ...

The acquisition is set to add Checkpoint's US Food and Drug Administration (FDA)-approved ... Sun Pharma received FDA approval in July l2024 for Leqselvi (deuruxolitinib), an oral treatment ...

These include slower-than-expected sales pick-up for key specialty brands, further delays in the launch of Leqselvi ... inhibitor drugs, which compete with Sun’s Ilumya brand, reported strong ...

Both drugs are already approved in the US ... sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology treatments, for an aggregate upfront price of $355m. The ...

They also considered Medicaid formularies and prior authorization criteria for coverage of Olumiant, Litfulo, and Leqselvi as of October 2024 ... Only Hawaii had unrestricted coverage of both drugs.

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...

Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss, a new study shows.